Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
15,66 EUR | 0,00% | 0,00% | 0,00% |
15/05 | Transcript : MedinCell S.A. - Special Call | |
14/05 | Medincell geeft update over Fase 3 klinische studie mdc-CWM | CI |
Omzet 2024 * | 13,96 mln. 15,14 mln. | Omzet 2025 * | 41,8 mln. 45,33 mln. | Marktkapitalisatie | 440 mln. 478 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -24,94 mln. | Nettowinst (verlies) 2025 * | 1 mln. 1,08 mln. | EV/omzet 2024 * | 35 x |
Nettoschuld 2024 * | 48,73 mln. 52,84 mln. | Nettoschuld 2025 * | 58,83 mln. 63,79 mln. | EV/omzet 2025 * | 11,9 x |
K/w-verhouding 2024 * |
-16,6
x | K/w-verhouding 2025 * |
-284
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 50,03% |
Recentste transcriptie over MedinCell
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 09-01-03 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 01-09-23 |
Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 05-07-17 |
Tone Kvåle
BRD | Director/Board Member | 55 | 13-06-22 |
Virginie Lleu
BRD | Director/Board Member | - | 25-05-16 |
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,59% | 727 mld. | |
-7,89% | 347 mld. | |
+15,66% | 319 mld. | |
+0,24% | 274 mld. | |
+13,29% | 238 mld. | |
+7,10% | 204 mld. | |
-5,81% | 203 mld. | |
+4,23% | 161 mld. | |
-1,70% | 160 mld. |
- Beurs
- Aandelen
- Koers MEDCL
- Koers